Clinical Trial: SWOG S2209

SWOG S2209

Status: Open

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

Eligible for screening study DCP 001

Completion of Pre-Registration QOLs is required after consent, prior to registration. Please see study documents.